Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Malaysian Genomics Resource Centre Bhd's current 3-Year Share Buyback Ratio was -5.00%.
XKLS:0155'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -265.6 Med: -3.2 Max: 0
Current: -5
During the past 13 years, Malaysian Genomics Resource Centre Bhd's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -265.60%. And the median was -3.20%.
XKLS:0155's 3-Year Share Buyback Ratio is ranked worse than 56.07% of 173
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.6
vs XKLS:0155: -5.00
Malaysian Genomics Resource Centre Bhd (XKLS:0155) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Malaysian Genomics Resource Centre Bhd 3-Year Share Buyback Ratio Related Terms
XKLS:0155 vs TMO, DHR, NTRA: 3-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malaysian Genomics Resource Centre Bhd 3-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's 3-Year Share Buyback Ratio falls into.
Malaysian Genomics Resource Centre Bhd 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -5.00 mean?
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a 3-Year Share Buyback Ratio of -5.00 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Malaysian Genomics Resource Centre Bhd and its competitors. According to the industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #97 out of 173 companies in the Medical Diagnostics & Research industry, placing it in the top 56.1%.
Is Malaysian Genomics Resource Centre Bhd's 3-Year Share Buyback Ratio too high?
Malaysian Genomics Resource Centre Bhd's current 3-Year Share Buyback Ratio is -5.00. Based on the distribution chart, Malaysian Genomics Resource Centre Bhd ranks #97 out of 173 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's 3-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #97 out of 173 companies for 3-Year Share Buyback Ratio. This places Malaysian Genomics Resource Centre Bhd in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 3-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Malaysian Genomics Resource Centre Bhd and its competitors. Malaysian Genomics Resource Centre Bhd's current 3-Year Share Buyback Ratio is -5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Modestly Overvalued. The stock's GF Value™ is RM0.31, compared to a current price of RM0.37 — trading 17.7% above its estimated fair value. The current 3-Year Share Buyback Ratio is -5.00. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current 3-Year Share Buyback Ratio is -5.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be overvalued.
The current stock price of RM0.37 is trading 17.7% above its estimated GF Value™ of RM0.31.
GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Modestly Overvalued.
Key valuation signals for XKLS:0155:
3-Year Share Buyback Ratio: -5.00
GF Value™: RM0.31 vs. price of RM0.37 (17.7% above fair value)
No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
47GF Score
Get the complete analysis for XKLS:0155
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0155 has been successfully added to your 
